Streetbeat News

Analyst Ratings

MKSI

MKS Instruments (NASDAQ:MKSI) has received mixed analyst ratings over the past three months, with a slight decrease in the average 12-month price target. Analysts have provided a range of price targets from $120 to $160, reflecting varied expectations. The company faces challenges with declining revenue, low net margins, and high debt levels.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 1:01 pm

ALV

Over the past three months, 12 analysts have evaluated Autoliv (NYSE:ALV), with ratings ranging from bullish to bearish. The average 12-month price target is $121.83, down from $131.11. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Autoliv faces revenue challenges and has a net margin below industry averages, but it has a strong ROE and ROA, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 1:00 pm

AVO

Lake Street analyst Ben Klieve has reiterated a Buy rating for Mission Produce (NASDAQ:AVO) with a maintained price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:00 pm

TNGX

Analysts have provided diverse ratings for Tango Therapeutics (NASDAQ:TNGX) over the past three months, with a majority being bullish. The average 12-month price target has increased by 17.6% to $14.5. Tango Therapeutics is a biotechnology company focused on precision oncology therapies, showing significant revenue growth but lagging behind industry peers.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 1:00 pm

AAPL

Rosenblatt analyst Barton Crockett maintains a Buy rating on Apple (NASDAQ:AAPL) with a price target of $261.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:00 pm

ZIM

Analysts have mixed views on ZIM Integrated Shipping, with recent ratings showing a shift towards bearish sentiment. The average 12-month price target is $17.24, slightly up from $17.18. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. ZIM's financial metrics show strong revenue growth and ROE, but challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 1:00 pm

CFB

CrossFirst Bankshares (NASDAQ:CFB) received mixed analyst ratings over the past three months, with a recent increase in the average 12-month price target to $19.5. Analysts have shown a bullish sentiment, with one 'Buy' and three 'Outperform' ratings. The company's financial performance is strong, with a high net margin and efficient debt management.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 1:00 pm

ORIC

Wedbush analyst David Nierengarten has reiterated an Outperform rating for ORIC Pharmaceuticals, maintaining a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 12:58 pm

SEAT

Craig-Hallum analyst Ryan Sigdahl maintains a Buy rating on Vivid Seats (NASDAQ:SEAT) but lowers the price target from $10 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 12:58 pm

AES

HTZ

NEE

VRT

Jim Cramer recommends buying Vertiv Holdings, citing its recent price drop. Vertiv's Q2 net sales rose 13% Y/Y, beating expectations. AES is described as 'very inexpensive' despite mixed Q2 results. NextEra Energy's stock is under review, while Hertz reported disappointing Q2 results.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 12:55 pm